Abstract:Objective: To observe the efficacy of programmed cell death 1 (PD-1) immunotherapy combined with bevacizumab for double-target anti-angiogenic therapy on stageⅣlung adenocarcinoma, and to analyze its influence on cellular immune function, short-term prognosis and adverse reactions. Methods: A total of 67 patients with stageⅣlung adenocarcinoma admitted to our hospital between December 2018 and August 2020 were selected in this study and they were divided into control group (n=33) and combined group (n=34) according to different treatment methods. Control group were treated with chemotherapy+PD-1 inhibitor, and combined group were treated with chemotherapy+PD-1 inhibitor+bevacizumab. The short-term treatment efficacy, changes of cellular immune function and Karnofsky performance status (KPS) score before and after treatment, adverse reactions and progression-free survival time were compared between the two groups. Results: The total effective rate of treatment and disease control rate of combined group were 29.41%and 79.41%respectively, which were significantly higher than 9.09%and 54.55%of control group (P<0.05). After treatment, the CD3+, CD4+and CD4+/CD8+in combined group were significantly higher than those in control group (P<0.05), and there was no significant difference in CD8+compared to control group (P>0.05). The increase and stable rate of KPS score of patients in combined group was significantly higher than that in control group (73.53%vs.45.45%) (P<0.05). There were no significant differences in the incidence of adverse reactions such as bone marrow suppression, gastrointestinal reactions, blood toxicity, liver-kidney functional damage and peripheral neurotoxicity in combined group compared with those in control group (P>0.05). The median progression-free survival time were 9.73 months in combined group and were 6.05 months in control group, with significant differences (P<0.05). Conclusion: PD-1 immunotherapy combined with bevacizumab for double-target anti-angiogenic therapy of stageⅣlung adenocarcinoma can significantly enhance the short-term treatment efficacy, improve the immune function, promote the quality of life and prolong the progression-free survival time.
